Dihydroergotamine Injection

157 interactions 472 cited references

Also sold as: DHE-45® Injection Migranal Trudhesa

About Dihydroergotamine Injection

Dihydroergotamine is used to treat migraine headaches (severe, throbbing headaches that sometimes are accompanied by nausea and sensitivity to sound and light) and cluster headaches (severe headaches usually on one side of the head or around one eye). Dihydroergotamine is in a class of medications called ergot alkaloid… Read the full Dihydroergotamine Injection drug information page →

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 9, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Erythromycin Zolmitriptan Fosamprenavir Itraconazole Indinavir Frovatriptan

62 Contraindicated 79 Major 16 Moderate

All (157) Contraindicated (62) Major (79) Moderate (16)

Major

Dihydroergotamine Injection Ranolazine Aspruzyo Increased exposure of CYP3A4 substrate Details Dihydroergotamine Injection Relacorilant Lifyorli Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Dihydroergotamine Injection Repotrectinib Augtyro Reduced CYP3A4 substrates exposure and reduced efficacy of CYP3A4 substrates Details Dihydroergotamine Injection Ritlecitinib Litfulo Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Dihydroergotamine Injection Schizandra Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Injection Selpercatinib Retevmo Increased substrate exposure and an increased risk for adverse effects Details Dihydroergotamine Injection Sevabertinib Hyrnuo Increased CYP3A substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Dihydroergotamine Injection Sibutramine An increased risk of serotonin syndrome (hypertension, hyperthermia, myoclonus, mental status changes) Details Dihydroergotamine Injection Sotorasib Lumakras Reduced exposure to CYP3A substrate and an increased risk of therapeutic failure Details Dihydroergotamine Injection Stiripentol Diacomit Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Injection Suzetrigine Journavx Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Dihydroergotamine Injection Taurursodiol Decreased exposure of the CYP3A4 substrate Details Dihydroergotamine Injection Tazemetostat Tazverik Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Dihydroergotamine Injection Tocilizumab Actemra Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Dihydroergotamine Injection Tovorafenib Ojemda Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Dihydroergotamine Injection Treosulfan Grafapex Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse and serious life-threatening toxicit... Details Dihydroergotamine Injection Verapamil Calan Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Injection Vonoprazan Voquezna Increased CYP3A substrates exposure Details Dihydroergotamine Injection Vorasidenib Voranigo Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Dihydroergotamine Injection Voxelotor Oxbryta Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Injection Zileuton Zyflo Increased ergot derivatives exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details

Moderate

Dihydroergotamine Injection Artemether Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Dihydroergotamine Injection Citalopram Celexa An increased risk of weakness, hyperreflexia and incoordination Details Dihydroergotamine Injection Escitalopram Lexapro An increased risk of weakness, hyperreflexia and incoordination Details Dihydroergotamine Injection Infliximab Avsola Decreased dihydroergotamine plasma concentrations Details Dihydroergotamine Injection Kratom Increased CYP3A substrate exposure Details Dihydroergotamine Injection Lapatinib Tykerb Increased exposure of dihydroergotamine Details Dihydroergotamine Injection Mavacamten Camzyos Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Dihydroergotamine Injection Metreleptin Altered exposure to dihydroergotamine Details Dihydroergotamine Injection Metronidazole Flagyl Increased plasma concentrations of ergot derivatives and increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Injection Nitroglycerin Gonitro Dihydroergotamine toxicity (peripheral ischemia, paresthesias, nausea, vomiting) Details Dihydroergotamine Injection Paroxetine Paxil An increased risk of weakness, hyperreflexia and incoordination Details Dihydroergotamine Injection Rilonacept Altered dihydroergotamine plasma concentrations Details Dihydroergotamine Injection Rilzabrutinib Wayrilz Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Dihydroergotamine Injection Sertraline An increased risk of weakness, hyperreflexia and incoordination Details Dihydroergotamine Injection Vilazodone Viibryd An increased risk of weakness, hyperreflexia and incoordination Details Dihydroergotamine Injection Vortioxetine Trintellix An increased risk of weakness, hyperreflexia and incoordination Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.